foxo4 dri senolytic peptide mechanism Molecular modelling of the FOXO4-TP53 interaction to design peptides for the elimination of senescent cancer cells Frontiers | FOXO4-DRI regulates endothelial

Philosophy of Care Dr

Important Safety Reminders Medical Supervision Required: AOD-9604 should only be used under qualified medical supervision Baseline and monitoring laboratory testing is recommended Individual contraindications and health status must be evaluated AOD-9604 is not FDA-approved for any indication Contraindications and Precautions: Pregnancy and breastfeeding (no safety data available) Active malignancy (discuss with oncologist) Pediatric use (not studied in children) Significant organ dysfunction (limited safety data) Report Concerns: Any unexpected symptoms or adverse effects should be reported to your healthcare provider promptly

In vitro and ex vivo academic studies show that AHK-Cu helps maintain the lifespan of dermal papilla cells and blocks pathways that lead to premature follicular miniaturization

Combining treatments should only be done as part of a medically supervised plan